Nrf2 inhibits M1 macrophage polarization to ameliorate renal ischemia-reperfusion injury through antagonizing NF-κB signaling

  • Int Immunopharmacol. 2024 Dec 25;143(Pt 1):113310. doi: 10.1016/j.intimp.2024.113310.
Hui Han  1 Yuanyuan Gao  1 Boxuan Chen  1 Hongjie Xu  1 Chenghao Shi  1 Xiaowu Wang  2 Yihan Liang  3 Zhixuan Wu  1 Ziqiong Wang  1 Yongheng Bai  4 Cunzao Wu  5
Affiliations
  • 1. Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325035, China.
  • 2. Department of Burns and Skin Repair Surgery, The Third Affiliated Hospital, Wenzhou Medical University, Ruian 325200, Zhejiang Province, China.
  • 3. Department of Urology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai 317000, China.
  • 4. Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325035, China. Electronic address: [email protected].
  • 5. Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325035, China. Electronic address: [email protected].
Abstract

Renal ischemia-reperfusion injury (IRI) is a condition that arises from a sudden interruption of the blood flow to the kidney for a period of time followed by restoration of the blood supply. This process contributes to acute kidney injury (AKI), increases morbidity and mortality, and is a major risk factor for chronic kidney disease (CKD). Nuclear factor erythroid-derived 2-like 2 (Nrf2) has been shown to exhibit strong anti-oxidative and anti-inflammatory effects, which are reciprocally regulated by the pro-inflammatory actions of nuclear factor-kappa B (NF-κB) signaling. In this study, we established a model of AKI caused by renal IRI in mice lacking the Nrf2 gene (KO-Nrf2) and mice pre-injected with ML385 (Nrf2 inhibitor). In addition, LPS- or IL-4-induced M1- or M2-type polarized macrophages (RAW264.7), respectively, were also treated with Nrf2 activation and inhibition. The results demonstrated a more pronounced activation of the NF-κB signaling pathway in the Nrf2 inhibition model, accompanied by a more severe inflammatory effect. In cultured macrophages and renal IRI mice, Nrf2 inhibition activated M1 macrophage polarization, thereby increasing the release of proinflammatory cell factors (iNOS and TNF-α) and aggravating renal IRI. Notably, the inhibitory effect of Nrf2 on M1 macrophage polarization was related to the downregulation of the NF-κB signaling pathway activity, resulting in partial relief of renal IRI. Consequently, our findings indicated that Nrf2 inhibits M1 macrophage polarization to ameliorate renal IRI through antagonizing NF-κB signaling. Targeted activation of Nrf2 may be one of the important strategies for renal IRI treatment.

Keywords
Inflammation; Ischemia-reperfusion injury (IRI); Macrophage polarization; NF-κB; Nrf2.
Products